Homepage Top Section2

The contract was signed through TaiGen’s subsidiary company TaiGen Biotechnology. Considering the competitiveness of the pharmaceutical market as well as concerns about proprietary information, the companies did not

CST-3056 is an alpha-1A adrenoceptor (α1A-AR) agonist, and is still in preclinical development. Alzheimer’s Drug Discovery Foundation co-founder and chief science officer Howard Fillit said: “Alpha-1A adrenoceptors are

LIVMARLI is claimed to be the first and only approved therapy in Taiwan used for treating cholestatic pruritus in patients with ALGS aged one year or older. Recently,

The 35,000ft2 facility, located inside the Ziggurat building, includes a cold chain, a warehousing, two single-use drug substance lines (50L and 500L scale HyPerforma DynaDrive), a buffer and

Kurma Partners’ Growth Opportunities Fund led the funding round, which has also seen participation from existing investors including Enterprise Ireland, Seroba Life Sciences, and Irish, US and Canadian

BBP-812 and BBP-631 are the lead assets of BridgeBio. An adeno-associated virus (AAV) 9 gene therapy, BBP-812 is intended to treat Canavan disease while BBP-631 is an AAV

With an investment of $38m, the company has doubled the manufacturing capacity of the facility. The expansion included new advanced analytical and chemical development laboratories and construction of

The deal value comprised an upfront cash payment of $1.75bn, apart from further milestone payments in the future. The parties entered an agreement in this regard in June 2023.

An investigational activin signalling inhibitor, sotatercept is intended for usage in adult PAH patients. A regulatory decision on the approval of the therapy is anticipated on 26 March